Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia (GAIA/CLL13)

Phase 3, 926 fit CLL patients without TP53 aberrations, randomized 1:1:1:1 to CIT (FCR or BR), Ven-R, Ven-O, or Ven-O-ibrutinib (12 cycles of venetoclax combinations). At month 15, undetectable MRD was 86.5% with Ven-O and 92.2% with Ven-O-I vs 52.0% with CIT (P<0.001 for both), and 57.0% with Ven-R (P=0.32 vs CIT). 3-year PFS 90.5% Ven-O-I vs 75.5% CIT (HR 0.32, 97.5% CI 0.19-0.54, P<0.001); 87.7% Ven-O (HR 0.42, P<0.001); 80.8% Ven-R (HR 0.79, P=0.18). Level 2 (MRD was a co-primary endpoint of a randomized trial, but treatment was not MRD-guided).

N Engl J MedPubMed 37163621